Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

Discover how UCSF is leading the charge in Long COVID research, uncovering key findings that advance our understanding of the condition. UCSF researchers have adapted innovative tools and ...

In the early months of the COVID-19 pandemic, UC San Francisco researchers were already seeing signs of lingering symptoms in ...

A recent study by South African academic Professor Nonhlanhla P. Khumalo has raised alarm over the risk of exposure to blood-borne viral infections during ...